Bourgeon Capital Management’s SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,822
| Closed | -$229K | – | 122 |
|
|
2025
Q1 | $229K | Buy |
2,822
+163
| +6% | +$13.2K | 0.05% | 100 |
|
|
2024
Q4 | $239K | Sell |
2,659
-12
| -0.4% | -$1.08K | 0.04% | 111 |
|
|
2024
Q3 | $264K | Buy |
2,671
+244
| +10% | +$24.1K | 0.05% | 95 |
|
|
2024
Q2 | $225K | Buy |
2,427
+135
| +6% | +$12.5K | 0.04% | 104 |
|
|
2024
Q1 | $217K | Buy |
2,292
+352
| +18% | +$33.4K | 0.04% | 106 |
|
|
2023
Q4 | $173K | Sell |
1,940
-2,352
| -55% | -$210K | 0.04% | 106 |
|
|
2023
Q3 | $313K | Buy |
4,292
+278
| +7% | +$20.3K | 0.07% | 86 |
|
|
2023
Q2 | $334K | Sell |
4,014
-163
| -4% | -$13.6K | 0.08% | 87 |
|
|
2023
Q1 | $318K | Buy |
4,177
+2,917
| +232% | +$222K | 0.08% | 82 |
|
|
2022
Q4 | $105K | Buy |
+1,260
| New | +$105K | 0.03% | 126 |
|